BACKGROUND: Tumor cell tissue factor (TF)-initiated coagulation supports hematogenous metastasis by fibrin formation, platelet activation and monocyte/macrophage recruitment. Recent studies identified host anticoagulant mechanisms as a major impediment to successful hematogenous tumor cell metastasis. OBJECTIVE: Here we address mechanisms that contribute to enhanced metastasis in hyperthrombotic mice with functional thrombomodulin deficiency (TM(Pro) mice). METHODS: Pharmacological and genetic approaches were combined to characterize relevant thrombin targets in a mouse model of experimental hematogenous metastasis. RESULTS: TF-dependent, but contact pathway-independent, syngeneic breast cancer metastasis was associated with marked platelet hyperreactivity and formation of leukocyte-platelet aggregates in immune-competent TM(Pro) mice. Blockade of CD11b or genetic deletion of platelet glycoprotein Ibα excluded contributions of these receptors to enhanced platelet-dependent metastasis in hyperthrombotic mice. Mice with very low levels of the endothelial protein C receptor (EPCR) did not phenocopy the enhanced metastasis seen in TM(Pro) mice. Genetic deletion of the thrombin receptor PAR1 or endothelial thrombin signaling targets alone did not diminish enhanced metastasis in TM(Pro) mice. Combined deficiency of PAR1 on tumor cells and the host reduced metastasis in TM(Pro) mice. CONCLUSIONS: Metastasis in the hyperthrombotic TM(Pro) mouse model is mediated by platelet hyperreactivity and contributions of PAR1 signaling on tumor and host cells.
BACKGROUND:Tumor cell tissue factor (TF)-initiated coagulation supports hematogenous metastasis by fibrin formation, platelet activation and monocyte/macrophage recruitment. Recent studies identified host anticoagulant mechanisms as a major impediment to successful hematogenous tumor cell metastasis. OBJECTIVE: Here we address mechanisms that contribute to enhanced metastasis in hyperthromboticmice with functional thrombomodulin deficiency (TM(Pro) mice). METHODS: Pharmacological and genetic approaches were combined to characterize relevant thrombin targets in a mouse model of experimental hematogenous metastasis. RESULTS:TF-dependent, but contact pathway-independent, syngeneic breast cancer metastasis was associated with marked platelet hyperreactivity and formation of leukocyte-platelet aggregates in immune-competent TM(Pro) mice. Blockade of CD11b or genetic deletion of platelet glycoprotein Ibα excluded contributions of these receptors to enhanced platelet-dependent metastasis in hyperthromboticmice. Mice with very low levels of the endothelial protein C receptor (EPCR) did not phenocopy the enhanced metastasis seen in TM(Pro) mice. Genetic deletion of the thrombin receptorPAR1 or endothelial thrombin signaling targets alone did not diminish enhanced metastasis in TM(Pro) mice. Combined deficiency of PAR1 on tumor cells and the host reduced metastasis in TM(Pro) mice. CONCLUSIONS:Metastasis in the hyperthrombotic TM(Pro) mouse model is mediated by platelet hyperreactivity and contributions of PAR1 signaling on tumor and host cells.
Authors: Bryce Kerlin; Brian C Cooley; Berend H Isermann; Irene Hernandez; Rashmi Sood; Mark Zogg; Sara B Hendrickson; Michael W Mosesson; Susan Lord; Hartmut Weiler Journal: Blood Date: 2003-11-13 Impact factor: 22.113
Authors: Begüm Kocatürk; Yascha W Van den Berg; Chris Tieken; J Sven D Mieog; Esther M de Kruijf; Charla C Engels; Martijn A van der Ent; Peter J Kuppen; Cornelis J Van de Velde; Wolfram Ruf; Pieter H Reitsma; Susanne Osanto; Gerrit-Jan Liefers; Vladimir Y Bogdanov; Henri H Versteeg Journal: Proc Natl Acad Sci U S A Date: 2013-06-25 Impact factor: 11.205
Authors: H Weiler; V Lindner; B Kerlin; B H Isermann; S B Hendrickson; B C Cooley; D A Meh; M W Mosesson; N W Shworak; M J Post; E M Conway; L H Ulfman; U H von Andrian; J I Weitz Journal: Arterioscler Thromb Vasc Biol Date: 2001-09 Impact factor: 8.311
Authors: J William Phillips; Kurt G Barringhaus; John M Sanders; Sean E Hesselbacher; Ann C Czarnik; David Manka; Dietmar Vestweber; Klaus Ley; Ian J Sarembock Journal: Circulation Date: 2003-04-21 Impact factor: 29.690
Authors: A L Darrow; W P Fung-Leung; R D Ye; R J Santulli; W M Cheung; C K Derian; C L Burns; B P Damiano; L Zhou; C M Keenan; P A Peterson; P Andrade-Gordon Journal: Thromb Haemost Date: 1996-12 Impact factor: 5.249
Authors: Eric Camerer; Aisha A Qazi; Daniel N Duong; Ivo Cornelissen; Rommel Advincula; Shaun R Coughlin Journal: Blood Date: 2004-03-18 Impact factor: 22.113
Authors: Gregory N Adams; Leah Rosenfeldt; Malinda Frederick; Whitney Miller; Dusty Waltz; Keith Kombrinck; Kathryn E McElhinney; Matthew J Flick; Brett P Monia; Alexey S Revenko; Joseph S Palumbo Journal: Cancer Res Date: 2015-08-03 Impact factor: 12.701
Authors: Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn Journal: Cancer Metastasis Rev Date: 2015-12 Impact factor: 9.264